Denileukin diftitox as novel targeted therapy for lymphoid malignancies. - Wikidata - wikimedia - TriplyDB

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

http://www.wikidata.org/entity/Q36946771

about

The role of regulatory T cells in cancer.In vivo depletion of CD4(+)CD25(hi) regulatory T cells is associated with improved antiviral responses in cats chronically infected with feline immunodeficiency virus Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma Inotuzumab ozogamicin as novel therapy in lymphomas.Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Receptor-directed therapy of T-cell leukemias and lymphomas.Optimizing denileukin diftitox (Ontak) therapy.Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine.Functions and uses of immunohistochemical stains in cutaneous infiltrates of hematopoietic origin: a review for the practicing dermatologist.Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox.

P2860

Q33631986-B04C769E-0C17-41CF-BF9B-5FCECE9EB805 Q33889113-F314583F-14DD-4C30-BC7A-639D22427FF1 Q34111789-1537F21E-4F60-4D99-8DE3-963E977A0504 Q34620271-6C964869-CF9D-4F2B-B07A-ADA58696679B Q34754395-35B02468-F62D-4C99-B656-F0E73F7C52F4 Q35882481-053C96A1-0B5F-43A4-95DA-790237568AA6 Q36273796-08A65D54-31E7-4914-BE3A-928F93FC9008 Q37196716-6CBCE581-1A09-4E5D-B2FE-C8513BA6E979 Q37236406-3C484D92-8CBE-4770-AB2F-B61597203A85 Q37729388-2ABDE8E2-BE6C-4ABB-AA71-BA6C54477FFC Q37863265-20564847-0024-4B34-8B26-9670D3801847 Q38501000-CC36E57A-7234-4F9F-8BCC-39CFEC39D121

P2860

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

http://www.wikidata.org/entity/Q36946771

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

@en

type

label

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

@en

prefLabel

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

@en

P1433

Q36946771-517DAE0B-28EC-43EA-B3FB-D6D48A860F51

P1476

Q36946771-B69B9FD8-C999-4866-B19A-185033F6A303

P2093

Q36946771-183792F8-01EA-48FF-B58C-25BFC6DC8F4B

Q36946771-8376671D-8DB5-4884-AA40-0402045B4160

Q36946771-ECE5F35F-36B8-4F03-9D19-9B9AED2A09DD

P2860

Q36946771-052F39C2-A047-436B-A36E-C5C21DA10A5A

Q36946771-1EF39D82-B18B-4587-AEB7-580FF1B4D6E1

Q36946771-2B41FEF8-4A8B-4104-9981-682C1C07A7EB

Q36946771-356510FA-0B44-4493-B4C3-BF80DC4428F7

Q36946771-51CE2CBA-3E70-40E9-9973-2DF50FDB86D7

Q36946771-7BC72B63-A85D-44D4-A5E9-4E44F158F6E8

Q36946771-7F78E8F4-35BE-4BD3-B72A-C40D7F00331D

Q36946771-90D4EAF0-A7F3-4827-95A6-571543B24883

Q36946771-9B6CFDA8-5E79-4EC3-836D-96CEDE95C82A

Q36946771-A3938A44-E1DE-4E06-B060-D613923BC6AD

P304

Q36946771-D69EF3B4-E6E8-436E-88E6-EFBAD8329623

P31

Q36946771-E1D40E62-D19E-41D0-9BA5-69D1CC107D93

P356

Q36946771-F277A396-4119-4291-976C-840BEF2F7DFD

P433

Q36946771-BB30B6DA-3B0D-43CA-BBA6-FA9573F726A7

P478

Q36946771-9F404AB4-CF2B-4252-807B-9F5281ABFC02

P577

Q36946771-B6C48D3F-35BD-4D93-AA28-C5F888DF7044

P698

Q36946771-9C288A4E-9BE7-4112-B2B8-E9DA7D5B2FA5

P356

07357900701360096

P1433

Cancer Investigation

P1476

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

@en

P2093

Bryan Y Wong

http://www.w3.org/2001/XMLSchema#string

Nam H Dang

http://www.w3.org/2001/XMLSchema#string

Stephanie A Gregory

http://www.w3.org/2001/XMLSchema#string

P2860

Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes

Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein

Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.

Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies.

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.

P304

495-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357900701360096

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17882663

http://www.w3.org/2001/XMLSchema#string